JNK activation is critical for Aplidin-induced apoptosis

Area of Science:

• Pharmacology
• Molecular Biology
• Cancer Research

Background:

• Aplidin is an established antitumor drug.
• It is known to induce apoptosis and activate signaling pathways like EGFR, Src, JNK, and p38MAPK.

Purpose of the Study:

• To elucidate the specific molecular targets and pathways critical for Aplidin's antitumor activity.
• To investigate the role of AP-1 and NF-kappaB family genes in Aplidin's mechanism of action.

Main Methods:

• Analysis of gene expression for AP-1 and NF-kappaB family members following Aplidin treatment.
• Assessment of AP-1 and NF-kappaB transcriptional activity.
• Utilizing genetically deficient mouse embryo fibroblasts (MEFs) lacking specific kinases (Src, JNK, p38MAPK) or transcription factors (c-Jun).
• Evaluating Aplidin sensitivity (IC50) in various cell lines, including proliferating vs. quiescent cells.

Main Results:

• Aplidin induces expression of AP-1 family genes (c-JUN, JUN B, JUN D, c-FOS, FRA-1, FOS B) and NF-kappaB component p65/RELA.
• c-FOS induction is dependent on EGFR, Src, and JNK/p38MAPK, while c-JUN and p65/RELA induction show partial or no dependence on these kinases.
• MEFs deficient in JNK isoforms are significantly less sensitive to Aplidin, indicating JNK's critical role.
• Cells with mutated JNK phosphorylation sites on c-Jun exhibit intermediate sensitivity.
• Aplidin exhibits higher cytotoxicity in proliferating cells, correlating with increased JNK activation.

Conclusions:

• JNK-mediated phosphorylation of c-Jun and other substrates is essential for Aplidin's cytotoxic and antitumor effects.
• The study identifies JNK and c-Jun as key mediators in Aplidin's mechanism of action.
• Differential pathway activation and cell proliferation status influence Aplidin efficacy.